NCT02129543招募中不适用
Collection of Peripheral Blood Samples From Donors and Recipients of Blood and Marrow Transplants for Laboratory Research in Immune Reconstitution
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 700
- 试验地点
- 1
- 主要终点
- Rate of Immune Reconstitution in Study Participants
研究概览
简要总结
This specimen collection lab protocol will allow the investigators to prospectively study immune reconstitution in patients being treated for hematologic disorders and immune factors affecting graft versus host disease in stem-cell transplant (SCT) patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Arm A: The study population will include subjects selected from all patients presenting to the clinical services of the Division of Hematology or Transplantation and Cellular Therapy. As a result, this group will consist of a diverse assortment including subjects ranging in age from late adolescence to approximately age 75; individuals of both sexes; and a wide variety of ethnic backgrounds. This will include patients with a broad range of hematologic malignancies and bone marrow failure states. We will attempt to study a broad range of patients and not exclude subjects on the basis of sex, ethnicity, age, or disease status in order to derive a more complete understanding of variables important in immune reconstitution. It is expected that up to 10 patients each month may be eligible for this study. Up to 200 patients may be enrolled in this arm.
- •Arm B: The study population will include subjects selected from all patients presenting to the clinical services of the Transplantation and Cellular Therapy Program as donors or recipients for SCT or cellular therapy. As a result, this group will consist of a diverse assortment including subjects ranging in age from late adolescence to approximately age 75; individuals of both sexes; and a wide variety of ethnic backgrounds. All donors will have been cleared for clinical marrow or peripheral blood stem cell donation, and will be expected to be generally healthy.
- •Recipients will include patients with a broad range of malignancies and will be among those selected as clinically fit to undergo SCT. Pregnant women will not be included among recipients, but may be present among donor subjects unless contraindicated for clinical purposes. For purposes of optimizing specific laboratory assays, subjects may be chosen on the basis of known serologic status (e.g., those with a history of positive immunoglobulin G (lgG) indicating a history of infection with cytomegalovirus (CMV), for assays of CMV-specific T cell function). While it may not be possible to study each patient presenting as a SCT recipient or donor, we will attempt to study a broad range of patients and not exclude subjects on the basis of sex, ethnicity, age, or disease status in order to derive a more complete understanding of variables important in immune reconstitution following SCT. It is expected that up to 6 patients each month may be eligible for this study.
- •Arm C: The study population will include patients undergoing Chimeric antigen receptor (CAR) T therapy.
- •This group of patients will include subjects ranging in age from late adolescence and adults of all ages, individuals of both sexes, and a wide variety of ethnic backgrounds. It is expected that up to 6 patients each month may be eligible for this arm of the study.
- •Age > 18 years old
- •Enrollment for treatment with Anti-tumor T cells including either CARs, T-cell receptor (TCR)-transgenic, tumor-infiltrating lymphocytes (TILs), or Tregs, or donor lymphocyte infusion (DLI).
- •White Blood Cell count > 100 k/microliter (uL).
- •Patients will be screened based on their enrollment and planned treatment with T cells. Up to 1 month prior to conditioning chemotherapy baseline samples will be collected, which can be pre-infusion product or blood samples. Post T cell infusion samples will be collected and this study will include fresh, non-cryopreserved cerebrospinal fluid (CSF),and/or bone marrow (BM), and/or blood and/or serum obtained from patients treated with adoptively transferred T cells. Patient PHI information will be stored on a password protected computer and the database file will be password protected to maximize security of protected health information (PHI). This file will be accessible by the study investigators.
- •Arm D: The goal of this aim is to study groups of subjects to understand immune function in individuals without cancer, as a reference group for studies of patients with cancer (including those receiving hematopoietic cell transplants and immune effector cell therapies). We also expect that these studies will have value independently to derive an understanding of protective human immunity in patients without cancer, but in relation to pathogen-specific immunity. This includes immunity to chronic viral infections (e.g., the herpesviruses that include Cytomegalovirus (CMV), Epstein-Barr virus (EBV),human herpesvirus-6 (HHV-6) and varicella zoster virus (VZV)), to epidemic and pandemic viruses (e.g., seasonal influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and to other pathogens (e.g., measles) that are important targets of antiviral immunity.
排除标准
- •Arms A, B, D: There are no exclusion criteria for this study.
研究组 & 干预措施
Arm A: Treatment for Malignancy/Failure Group
Participants in this group will be those who are undergoing treatment for hematologic malignancy or bone marrow failure state.
干预措施: Blood Draw (Procedure)
Arm B: Standard-of-Care SCT Group
Participants in this group will be cancer participants being treated with standard of care stem cell therapy
干预措施: Blood Draw (Procedure)
Arm C: Adoptive T Cell Therapy Group
Participants in this group will be participants being treated with adoptive T cell therapy.
干预措施: Blood Draw (Procedure)
Arm D: Control Group
Participants without cancer for studies of immunophenotype and immunologic function.
干预措施: Blood Draw (Procedure)
结局指标
主要结局
Rate of Immune Reconstitution in Study Participants
时间窗: 1 year
The rate of immune reconstitution in study participants treated for hematologic disorders and malignancies including SCT donors and recipients.
次要结局
- T cell subsets derived from samples for participants receiving stem cell therapy(1 year)
- Immune status of responders and non-responders to CAR-T therapy(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
PDAC Peripheral and Portal Vein SamplingPancreatic AdenocarcinomaNCT04289961The Christie NHS Foundation Trust26
已完成
早期 1 期
Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the USTuberculosisNCT03175380Aeras15
已完成
不适用
Study Vitamin D in Healthy IndividualsVitamin D DeficiencyNCT02250625Fujirebio Diagnostics, Inc.482
招募中
不适用
Blood Sampling of Healthy Volunteers for Immunological ResearchHealthy VolunteersNCT03819829The Netherlands Cancer Institute50
招募中
不适用
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy VolunteersHealthy SubjectHematologic and Lymphocytic DisorderHematopoietic and Lymphoid Cell NeoplasmImmune System DisorderMalignant NeoplasmNCT03207854University of Southern California500